Emergent Biodefense Drug Patent Portfolio

Emergent Biodefense owns 1 orange book drug protected by 5 US patents Given below is the list of Emergent Biodefense's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10112909 Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof 10 Oct, 2034
Active
US10487061 Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof 10 Oct, 2034
Active
US8962829 Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof 10 Oct, 2034
Active
US9371344 Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof 10 Oct, 2034
Active
US9303051 Phosphonate ester derivatives and methods of synthesis thereof 31 Aug, 2031
Active


Given below is the list of recent legal activities going on the following drug patents of Emergent Biodefense.

Activity Date Patent Number
Patent litigations
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US9303051
transaction for FDA Determination of Regulatory Review Period 07 Feb, 2024 US9303051
Payment of Maintenance Fee, 8th Year, Large Entity 06 Dec, 2023 US9371344
Payment of Maintenance Fee, 8th Year, Large Entity 20 Sep, 2023 US9303051
Payment of Maintenance Fee, 4th Year, Large Entity 10 May, 2023 US10487061
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 14 Feb, 2023 US9371344
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 14 Feb, 2023 US8962829
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 14 Feb, 2023 US9303051
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 14 Feb, 2023 US10112909
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 08 Feb, 2023 US10487061
Change in Power of Attorney (May Include Associate POA) 10 Jan, 2023 US10487061
Email Notification 10 Jan, 2023 US10487061
Change in Power of Attorney (May Include Associate POA) 10 Jan, 2023 US10112909
Email Notification 10 Jan, 2023 US10112909
Email Notification 09 Jan, 2023 US9303051


Emergent Biodefense's Family Patents

Emergent Biodefense drugs have patent protection in a total of 15 countries. It's US patent count contributes only to 26.9% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Emergent Biodefense Drug List

Given below is the complete list of Emergent Biodefense's drugs and the patents protecting them.


1. Tembexa

Tembexa is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10112909 Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof 10 Oct, 2034
(10 years from now)
Active
US10487061 Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof 10 Oct, 2034
(10 years from now)
Active
US8962829 Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof 10 Oct, 2034
(10 years from now)
Active
US9371344 Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof 10 Oct, 2034
(10 years from now)
Active
US9303051 Phosphonate ester derivatives and methods of synthesis thereof 31 Aug, 2031
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tembexa's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List